Preoperative Platelet/Albumin Ratio Predicts Morbidity and Mortality in Patients with Retroperitoneal Liposarcoma

Retroperitoneal sarcomas are a rare and heterogeneous group of malignant neoplasms. The most frequent sarcoma in this location is liposarcoma; complete resection is the gold standard of treatment. To achieve this, a multivisceral resection is often necessary to reduce local recurrence. However, this approach must be balanced by the potential for added morbidity. This study aims to evaluate the platelet-albumin ratio as a predictor of morbidity risk. A retrospective review of the medical records of patients with retroperitoneal liposarcomas operated with curative intent at our institution between January 2010 and December 2020 was performed. The platelet-albumin ratio was calculated, and a cutoff point of 78.86 was determined to predict morbidity by receiver operating characteristic (ROC) curve analysis, divided into high-risk and low-risk groups with a sensitivity of 83% and a specificity of 71.6%. These risk groups were contrasted with the different demographic and evolution variables. One hundred thirty-six patients were analyzed, and 91 met the inclusion criteria; age at presentation was 52.55 years (SD 12.96), tumor size was 29.31 (SD 12.43), and 40.7% underwent multivisceral resections, identifying a difference between the presence of a high platelet/albumin ratio and the appearance of complications at 30 days with an OR of 8 (CI 1.0052 to 63.6698, p 0.0494). The platelet-albumin ratio is an easy-to-use test that could help clarify the group of patients who require preoperative prehabilitation to reduce significant complications.